Fecal Microbiota Transplantation Superior to Fidaxomicin for Recurrent C Difficile Infection
Data from a study presents compelling evidence for the superiority of FMT in multiply recurrent CDI.
Clostridioides Difficile
Clostridioides difficile
Feature Article
Latest News
Calcineurin Inhibitors May Increase Risk for Community-Acquired Clostridioides difficile Infection
Investigators conducted a retrospective study to better understand whether there is an equally shared risk for C difficile infection across immunosuppressant classes.
Management of Clostridioides difficile Infection in Adults: 2021 Clinical Practice Guidelines
A multidisciplinary panel comprising members from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America created guidelines for health care professionals caring for patients with C difficile infection.
Recurrence of Clostridioides difficile Infection Less Frequent Among Transplant Recipients Treated With Bezlotoxumab
Investigators evaluated the safety and effectiveness of bezlotoxumab to prevent recurrent C difficile infection in patients having undergone solid organ or hematopoietic cell transplantation.
Low Immune Response to Clostridioides difficile Treatment in Immunosuppressed Patients
Investigators assessed the immune response to Clostridioides difficile in immunocompromised patients.
Study Finds Fidaxomicin More Effective Than Metronidazole, Vancomycin for Clostridioides difficile Infection
Investigators assessed whether choice of antibiotic has an impact on shedding of Clostridioides difficile spores in hospitalized patients.
Probiotic Use Ineffective for Primary Prevention of Clostridioides difficile Infection in Select Hospitalized Patients
A team of investigators evaluated outcomes following probiotic use for primary prevention of Clostridioides difficile infection in hospitalized patients.
Guidelines Issued for Clostridioides difficile Management in Adults
Authors recommend against probiotics for prevention of CDI; in those with CDI recurrence, FMT recommended to prevent further recurrence.
Overcoming Current Challenges in the Development of Microbiome Drugs
To develop microbiome drugs, scientists will need to address challenges in safety, uniformity, and delivery.
Disinfectant Wipes Transfer C Difficile Spores
Study authors tested the effect of disinfectant wipes on spore loads and cross-contamination risk for Clostridioides difficile.
Revised Clostridioides difficile Practice Guidelines Had Significant Effect on Treatment Decisions
Publication of the revised clinical practice guidelines for Clostridioides difficile infection was followed by significant increases in use of oral vancomycin and fidaxomicin, and a significant decrease in use of oral metronidazole.
Microbiome-Based Therapy Looks Promising for Recurrent C Difficile Infection
“These positive preliminary findings represent a major step forward towards bringing an innovative, non-antibiotic option to patients that may help restore their gut microbiome,” said Per Falk, Ferring’s President and Chief Science Officer.
National Burden of C difficile Infection Decreased From 2011 Through 2017
As a result of a decline in healthcare–associated infections, the estimated burden of Clostridioides difficile infection in the United States decreased by an adjusted 24% from 2011 through 2017.
Burden of Clostridioides difficile Infection Down in the U.S.
From 2011 to 2017, there was a decrease in the estimated national burden of Clostridium difficile infection.
Changes in Microbiota Predictive of Recurrent C Difficile Infection Risk
Features of fecal microbiota at baseline and after antibiotic therapy may be predictive of recurrent Clostridiodes difficile infection in patients with and without ulcerative colitis.
Glutamate Dehydrogenase Test Reduces Isolation for C difficile Infection
A glutamate dehydrogenase test for Clostridioides difficile may reduce unnecessary isolation time for patients.
Fidaxomicin Approved for C difficile-Associated Diarrhea in Pediatric Patients
The FDA has approved fidaxomicin for the treatment of Clostridioides difficile-associated diarrhea in adult and pediatric patients aged 6 months and older.
Prevalence and Length of Hospital Stay for Clostridioides difficile Infections
Clostridioides difficile infection is associated with a large burden on the healthcare system in the United States.
Dual Therapy for C difficile Infection Not Superior to Vancomycin Alone
Dual therapy with intravenous metronidazole and oral vancomycin is not superior to oral vancomycin alone in the treatment of Clostridioides difficile infections.
One in 10 Hospital Patients May Carry C difficile at Admission
Asymptomatic carriers of C. difficile at significant risk for progression to symptomatic infection
Toxin Enzyme Immunoassay Identifies Severe Clostridioides difficile Infections
Toxin enzyme immunoassay more accurately identifies severe C difficile infections from strains more likely to cause recurrence, but otherwise had similar results for complications and mortality compared with the standard nucleic acid amplification test.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Clostridioides Difficile
Loading... 
Loading...